Asianet Newsable on MSN

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today ...

Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates

Reports third quarter revenue of $1.0 billion, GAAP net loss of $ (0.2) billion and GAAP EPS of $ (0.51) Improves 2025 ...

Sensus SRTS Q3 2025 Earnings Call Transcript

CMS Reimbursement Codes -- The Centers for Medicare & Medicaid Services (CMS) approved dedicated CPT codes for superficial ...

Hereditary cancer, high cholesterol risk for 100,000 Canadians to be checked in genetic screening project

Over the the next five years, up to 100,000 people in Ontario will be screened for genetic conditions that increase their ...
PharmExec

FDA Approves Johnson and Johnson’s Caplyta

Caplyta is now FDA-approved for MDD treatment in adults, marking its fourth indication, including bipolar I and II depression ...
The American Journal of Managed Care

FDA Approves Lumateperone as Add-On Therapy for Major Depressive Disorder

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

Eli Lilly says its next generation weight loss drug has shown promise in early trials

Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and ...
Filter

Landmark Ruling Fortifies Canada’s “Good Samaritan” Overdose Law

Harm reductionists see the decision, protecting people from possession arrests at overdose scenes, as a vital win in a ...